Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Coronaviruses
  4. Volume 6, Issue 2
  5. Article
Volume 6, Issue 2
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Background

Critically ill patients with COVID-19 have important risk factors for drug–drug interactions.

Objective

This study aimed to characterize and describe the profile and management of drug–drug interactions in critically ill patients affected by COVID-19 in a tertiary care hospital in Colombia.

Methods

A descriptive retrospective cohort with an exploratory analytical component was used. The medical records of 191 patients were reviewed from August 2020 to February 2021. An initial descriptive analysis was performed, and a bivariate analysis was developed to include variables of significance in a multivariate analysis.

Results

In our cohort of critically ill patients, the following factors were associated with a higher risk of major outcome development: a higher age ( = 0.037), Charlson comorbidity index (CCI) ( = 0.001), Sequential Organ Failure Assessment (SOFA) score ( = 0.001), a greater number of prescribed drugs, number of interactions, and the presence of type-D interactions.

Conclusion

Identifying clinical predictors and types of drug interactions may alter the development of major outcomes such as mortality.

© 2025 Bentham Science Publishers
© 2025 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975276067240227081312
2024-03-06
2025-05-30

  • From This Site

    /content/journals/covid/10.2174/0126667975276067240227081312
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. BistaD. PalaianS. ShankarP.R. PrabhuM.M. PaudelR. MishraP. Understanding the essentials of drug interactions: A potential need for safe and effective use of drugs.KUMJ200753421430
     [Google Scholar]
  2. LeapeL.L. BrennanT.A. LairdN. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II.N. Engl. J. Med.1991324637738410.1056/NEJM199102073240605 1824793
     [Google Scholar]
  3. de SociedadE. Sociedad española de farmacia hospitalaria. Introducción a las interacciones farmacológicas.2012Available from https://wwwsefhes/bibliotecavirtual/interacc2014/InteraccionesFarmacoloigicas_prpdf
  4. SeymourR.M. RoutledgeP.A. Important drug-drug interactions in the elderly.Drugs Aging199812648549410.2165/00002512‑199812060‑00006 9638396
     [Google Scholar]
  5. HernándezM. TribiñoG. BustamanteC. Caracterización de las potenciales interacciones farmacológicas en pacientes de una unidad de cuidados intensivos en un Hospital de Tercer Nivel de Bogotá.Biomédica201838340741610.7705/biomedica.v38i4.3884 30335246
     [Google Scholar]
  6. INVIMA-Instituto Nacional de Vigilancia de Medicamentos y Alimentos ABC-Seguridad en el Uso de Medicamentos.2021Available from: https://www.invima.gov.co/documents/20143/453029/CARTILLA+2+-+SEGURIDAD+EN+EL+USO+DE+MEDICAMENTOS.PDF/532594f2-c02e-416d-77c4-2200622d6c64
  7. Pan American Health Organization WHO characterizes COVID-19 as a pandemic.2020Available from: https://www.paho.org/en/news/11-3-2020-who-characterizes-covid-19-pandemic
  8. HidaA. AberouchL. FaroudyM. ChaibiA. Participation of a pharmacist in patient care for critically ill COVID-19 patients in Morocco: A prospective study.Pharma Clin202358432933810.1016/j.phacli.2023.01.003
     [Google Scholar]
  9. BeningerP. Drug-drug interactions: An overlooked dimension of the COVID-19 pandemic.Clin. Ther.202345538738810.1016/j.clinthera.2023.04.008 37164778
     [Google Scholar]
  10. RahmadaniI.D. IrawatiS. WibowoY.I. SetiadiA.P. Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities.PeerJ202311e1507210.7717/peerj.15072 37397011
     [Google Scholar]
  11. ChenZ. TianF. ZengY. Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients.BMC Geriatr.202323177410.1186/s12877‑023‑04487‑9 38001406
     [Google Scholar]
  12. EsmaeiliA. NiazkhaniZ. MakhdoomiK. Potential drug-drug interactions in a multi-center study of death cases of COVID-19: The significance of appropriate drug choice.Int. J. Clin. Pharmacol. Ther.2023611253154210.5414/CP204469 37877293
     [Google Scholar]
  13. European Medicines Agency ICH E6 (R2) Good clinical practice United Kingdom.2016Available from: https://www.ema.europa. eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf
  14. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects.JAMA2013310202191219410.1001/jama.2013.281053 24141714
     [Google Scholar]
  15. Perioperative uses of intravenous opioids: Specific agents.Up- ToDate2022
     [Google Scholar]
  16. CharlsonM.E. PompeiP. AlesK.L. MacKenzieC.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation.J. Chronic Dis.198740537338310.1016/0021‑9681(87)90171‑8 3558716
     [Google Scholar]
  17. Martínez CeldranL.M. Guevara FerrandoJ. Moreno RoyoL. Do we know all the pharmacological interactions? The OATP1B1 transporter.Farm. Comunitarios2018104293210.5672/FC.2173‑9218.(2018/Vol10).004.06
     [Google Scholar]
  18. SK SR Anuba PA, Swetha B, Aishwarya PM, Sabarathinam S. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases.Diabetes Metab. Syndr.202216310245110.1016/j.dsx.2022.102451 35279008
     [Google Scholar]
  19. MaJ. ClineD.M. TintinalliJ.E. KelenG.D. StapczynskiS. Emergency Medicine Manual.6th edNew YorkMcGraw-Hill2004
     [Google Scholar]
  20. QadirN. ChangS.Y. Pharmacologic treatments for acute respiratory distress syndrome.Crit. Care Clin.202137487789310.1016/j.ccc.2021.05.009 34548139
     [Google Scholar]
  21. RosenD.S. MacdonaldR.L. Subarachnoid hemorrhage grading scales: A systematic review.Neurocrit. Care20052211011810.1385/NCC:2:2:110 16159052
     [Google Scholar]
  22. TorbicH. DuggalA. Neuromuscular blocking agents for acute respiratory distress syndrome.J. Crit. Care20194917918410.1016/j.jcrc.2018.10.019 30396789
     [Google Scholar]
  23. MurrayM.J. CowenJ. DeBlockH. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient.Crit. Care Med.200230114215610.1097/00003246‑200201000‑00021 11902255
     [Google Scholar]
  24. ChaudhariS. WankhedkarK. Popis-MatejakB. BaumsteinD. Methadone for fun sake… Kidneys are at stake!!!Am. J. Ther.2016234e1108e110910.1097/MJT.0000000000000172 25782567
     [Google Scholar]
  25. CaribéR.A. ChavesG.R. PocognoniJ.D. SouzaI.A. Potenciales interacciones medicamentosas en pacientes con sepsis internados en la unidad de terapia intensiva.Farm. Hosp.2013375383387 24128100
     [Google Scholar]
  26. WangP.P. HuangE. FengX. Opioid-associated iatrogenic withdrawal in critically ill adult patients: A multicenter prospective observational study.Ann. Intensive Care2017718810.1186/s13613‑017‑0310‑5 28866754
     [Google Scholar]
/content/journals/covid/10.2174/0126667975276067240227081312
Loading
FARMACOVID: Longitudinal Study of the Profile and Management of Drug Interactions in Critically Ill Patients with COVID-19
Coronaviruses 6, E060324227738 (2025); https://doi.org/10.2174/0126667975276067240227081312
/content/journals/covid/10.2174/0126667975276067240227081312
/content/journals/covid/10.2174/0126667975276067240227081312
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): bivariate analysis; COVID-19; Drug-interactions; genetic variations; mortality; type-D interactions

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test